Novartis' blockbuster immunology drug cosentyx has disappointed in a phase 3 trial involving patients with giant cell arteritis (gca), a debilitating autoimmune disease affecting the. Anonymous discussion boards for medical equipment/device companies
Best Superbowl Commercial 2025 - Richard W. Davis




